Video

Dr. Miller on the Current Treatment Landscape of Ovarian Cancer

Eirwen M. Miller, MD, discusses the current treatment landscape of ovarian cancer.

Eirwen M. Miller, MD, a gynecologic oncologist at Allegheny Health Network, West Penn Hospital, discusses the current treatment landscape of ovarian cancer.

The treatment landscape of ovarian cancer has evolved rapidly in recent years, specifically with ongoing clinical trials examining the role of immunotherapy with or without a PARP inhibitor in the up-front maintenance setting, Miller explains. Results from these trials are highly anticipated, as they could help refine up-front maintenance therapy in the platinum-resistant setting before potentially moving treatments to the frontline setting, Miller says. 

Trials are also examining antibody-drug conjugates and monoclonal antibodies, Miller notes. Overall, ovarian cancer has new data that continues to provide more options and is pushing the treatment landscape forward, Miller concludes.

Related Videos
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD